News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Galapagos NV (GLPG.BR) Release: First Clinical Centers Opened For Phase 2 Crohn's Study With GLPG0634


1/30/2014 8:59:40 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MECHELEN, Belgium, Jan. 29, 2014 (GLOBE NEWSWIRE) -- Galapagos NV (Euronext: GLPG) announced today that the first clinical centers have been opened for enrolment in the Phase 2 clinical study in Crohn's disease with GLPG0634, a selective JAK1 inhibitor. The Phase 2 study will evaluate the efficacy and safety of GLPG0634 during 20 weeks of treatment in 180 patients with active Crohn's disease.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES